Medical Microbiology articles for Canada

Time frame: 1 May 2025 - 30 April 2026

View topic

Count: 65

Article ‘Count’ for Medical Microbiology.

Journal Count Share
1 0.57
Transparent UV-Curable Self-Sanitizing Coatings Applicable to Diverse Surfaces and High-Touch Screens to Mitigate Deadly Pathogen Transmission 0.57
1 0.04
Estimating the effect of hepatitis C infection on multidrug-resistant tuberculosis treatment outcomes under hypothetical interventions on regimen composition and adherence 0.04
1 0.20
Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity 0.20
7 3.82
Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years 0.10
Real-World Effectiveness of RSVpreF and RSVpreF3 Vaccines in Preventing Hospitalisation and Emergency Department Visits Associated with Respiratory Syncytial Virus in Older Adults: A Meta-Analysis 0.83
Gaps in the Hepatitis C Prenatal and Postpartum Care Cascade: Rationale for Treatment in Pregnancy 0.92
HBV Care Cascade in Rwanda: A Population-based Study From 2016–2023 0.82
Clinical predictors and incidence of Kaposi sarcoma among males with HIV in the Treat-all era in the United States and Canada 0.10
Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for RSV Disease Aged 18 to 59 Years 0.05
The Burden of Antimicrobial Resistant Bacteremia in Ontario: A Population-Wide Analysis of Attributable Mortality From 110 Pathogen-Antibiotic Combinations 1.00
3 0.27
HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER) 0.17
Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT study 0.07
Helicobacter pylori antibiotic resistance: a global challenge in search of solutions 0.03
1 1.00
Nirsevimab Against Hospitalizations and Emergency Department Visits for Lower Respiratory Tract Infection in Infants 1.00
3 1.81
Structural and mechanistic basis of ubiquitous bacterial kinase signaling identifies PorX as a noncanonical substrate in Porphyromonas gingivalis 0.69
The biosynthesis of N-acylated tryptazolone in Mycobacterium tuberculosis and related bacteria 1.00
A Variant of the MenB Strain of Synechocystis sp. PCC 6803 Disrupts a Stress Response Pathway Allowing DMPBQ to Occupy the A1 Sites of Photosystem I 0.11
1 0.16
P selectin promotes SARS-CoV-2 interactions with platelets and the endothelium 0.16
2 1.09
A single-cell atlas of the woodchuck liver reveals cellular programs conserved in human HBV infection 1.00
Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program 0.09
7 5.82
Monkeypox Virus Shedding Despite Tecovirimat Treatment in a Cohort in Toronto, Canada 1.00
Incidence of Respiratory Syncytial Virus-Associated Hospitalization Among Adults in Ontario, Canada, 2017–2019 1.00
Assessing the Potential of Sexual Transmission of Lassa Virus in a Natural Rodent Reservoir 0.80
Monkeypox Virus Transcriptional Profiles and Host Responses in Skin Lesion Swabs Among Individuals With Human Immunodeficiency Virus 1.00
The Choice of Viral Load End Point in Early Phase Trials of COVID-19 Treatments Aiming to Reduce 28-Day Hospitalization and/or Death 0.09
Functional and Structural Characterization of Treatment-Emergent Nirmatrelvir Resistance Mutations at Low Frequencies in the Main Protease (Mpro) Reveals a Unique Evolutionary Route for SARS-CoV-2 to Gain Resistance 0.96
Recovery of Antibody Immunity After a Resurgence of Respiratory Syncytial Virus Infections 0.97
1 1.00
Respiratory Syncytial Virus (RSV)‐Related Hospitalization and Increased Rate of Cardiovascular Events in Older Adults 1.00
1 0.07
Targeting de novo purine biosynthesis for tuberculosis treatment 0.07
16 6.90
Biophysical characterization of Eag chaperones suggests the mechanism of effector transmembrane domain release 1.00
Highly replicating hepatitis C virus variants emerge in immunosuppressed patients causing severe disease 0.04
Staphylococcus aureus induces Gasdermin A-dependent keratinocyte pyroptosis 0.29
The assembly of a hybrid type IV secretion system by a Crohn’s disease-associated strain 0.77
The bactericidal FabI inhibitor Debio 1453 clears antibiotic-resistant infection in vivo 0.13
Effect of intrapartum azithromycin on early childhood gut mycobiota development: post hoc analysis of a double-blind randomized trial 0.08
Coniontins, lipopetaibiotics active against identified from a microbial natural product fractionation library 1.00
The structure of the Tad pilus alignment complex reveals a periplasmic conduit for pilus extension 0.33
Disruption of the ATP-dependent unfoldase ClpX reverses antifungal resistance in Cryptococcus neoformans 0.85
Human protein interaction networks of ancestral and variant SARS-CoV-2 in organ-specific cells and bodily fluids 0.95
Colistin enhances caspofungin antifungal efficacy against by modulating calcium homeostasis and stress responses 0.31
A shared inflammatory signature across severe malaria syndromes manifested by transcriptomic, proteomic and metabolomic analyses 0.03
Macrophage-augmented intestinal organoids model virus-host interactions in enteric viral diseases and facilitate therapeutic development 0.02
T cell memory response to MPXV infection exhibits greater effector function and migratory potential compared to MVA-BN vaccination 0.00
Structural basis of TMPRSS11D specificity and autocleavage activation 1.00
Single-dose replicon RNA Sudan virus vaccine uniformly protects female guinea pigs from disease 0.09
1 0.03
A scalable gut epithelial organoid model reveals the genome-wide colonization landscape of a human-adapted pathogen 0.03
2 0.23
Improved VSV-Ebola-GP booster vaccination approach promotes antibody affinity maturation and durable anti-Ebola immunity in humans 0.13
Bat organoids reveal antiviral responses at epithelial surfaces 0.10
2 0.11
Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial 0.05
Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns 0.06
1 0.88
Expansion of the functional genomics GRACE library reveals genes relevant for temperature-dependent fitness in Candida albicans. 0.88
2 1.17
Twitching motility suppressors reveal a role for FimX in type IV pilus extension dynamics. 0.67
Polymerization and flanking domains of the bactofilin BacA collectively regulate stalk formation in Asticcacaulis biprosthecum 0.50
1 0.02
Passive immunotherapy for adults hospitalized with COVID-19: An individual participant data meta-analysis of six randomized controlled trials 0.02
1 0.28
Ebola virus matrix protein VP40 triggers inflammatory responses linked to the ebolavirus virulence 0.28
1 0.04
Pre-European contact leprosy in the Americas and its current persistence 0.04
1 0.76
Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis 0.76
1 0.94
Human retinoic acid–inducible gene I (RIG-I) deficiency associated with susceptibility to classic Kaposi sarcoma 0.94
2 0.06
Feasibility of interrupting the transmission of soil-transmitted helminths: the DeWorm3 community cluster-randomised controlled trial in Benin, India, and Malawi 0.01
Epidemiology and phylogenomic characterisation of two distinct mpox outbreaks in Kinshasa, DR Congo, involving a new subclade Ia lineage: a retrospective, observational study 0.05
1 0.03
Treatment of chronic hepatitis B in Ethiopia: 1-year results from a real-life, multicentre, prospective cohort study 0.03
1 0.11
Incidence and prevalence of antimicrobial resistance in outpatients with cancer: a multicentre, retrospective, cohort study 0.11
3 0.36
Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients 0.29
Clesrovimab for Prevention of RSV Disease in Healthy Infants 0.04
Marburg Virus Disease in Rwanda, 2024 — Public Health and Clinical Responses 0.03

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.